The results of transplantation with unrelated donors, compared to sibling transplantations, are inferior due to an increased incidence and severity of GVHD, graft rejection and infections. [2] [3] [4] Additionally, the chance of identifying a matched unrelated donor is approximately 50% for Caucasians, but less than 10% for ethnic minorities and progression of the disease might occur during the search for an unrelated donor. 5 Due to immediate availability, the possibility of using a haploidentical donor independent of HLA-matching would offer a number of advantages. Almost all patients who may benefit from allogeneic transplantation would have a donor within a certain time-frame. In contrast to the use of cord blood cells as the stem cell source, 6 the haploidentical donor is still available in the case of nonengraftment or rejection and is also readily available for possible future strategies of post-transplant immunotherapy such as donor lymphocyte infusion. 7 However, haploidentical T celldepleted transplants were associated in the past with an increased incidence of acute and chronic GVHD, nonengraftment or graft rejection and prolonged immunodysregulation increasing the risk of fatal infections and lymphoproliferative disorders. 8, 9 In animal studies, it has been shown that increasing the number of transplanted mismatched stem cells completely depleted of T cells, can overcome the HLA barrier and sustained engraftment can be achieved in the absence of acute and chronic GVHD and other severe side-effects. 10 Moreover, it was found in man that the combination of T celldepleted bone marrow with peripheral blood stem cells from haploidentical donors led to sustained engraftment in adult patients. 11 However, delayed immune recovery was still observed in adult patients transplanted with T celldepleted PBPC resulting in a high mortality rate due to fatal infections. 12 Considering that, due to the lower body weight of children, high numbers of CD34 ϩ stem cells can be transplanted and the faster immune reconstitution seen in children, we investigated whether the transplantation from parental donors of megadoses of G-CSF-mobilized CD34 ϩ progenitor cells, completely depleted of T cells by positive selection of CD34 ϩ progenitors using the method of magnetic-activated cell sorting (MACS), can safely reconstitute myelo-and lymphopoiesis in children with malignant and nonmalignant diseases after myeloablative therapy for whom no suitable donor could be identified in a reasonable time.
Patients and methods
Thirty-nine children with various diseases (16 acute lymphoblastic leukemia, five acute myeloblastic leukemia, four myelodysplastic syndrome, three chronic myeloid leukemia, three malignant lymphoma, six immunodeficiency, one osteopetrosis and one severe aplastic anemia) were included in this study. The median weight of the patients was 20 kg (range 5-66) and the median age 7.25 years (range 0.5 to 18). Among the 31 patients with malignant diseases, 14 had resistant disease and were not in remission or even had progressive disease prior to transplantation. The status of disease at time of transplantation is shown in Table 1 . Informed consent was obtained from the parents. According to the judgment of the attending physicians, none of the patients would have had a realistic chance of survival without this treatment modality.
Donors, stem cell mobilization and collection
For 36 patients, parental donors (father 24, mother 12) were used. In three patients, the stem cell donor was an adult brother. HLA typing was performed by standard serological analysis and polymerase chain reaction with sequence-specific oligonucleotide probes. Twenty-six donors had a three HLA-loci mismatch, eight donors were two-loci and five were one-locus mismatched. The PBPC were mobilized with G-CSF (Neupogen; Amgen, Munich, Germany; 10 g/kg/day) for 6 days and stem cell collection was performed on days 5 and 6 using either a Fenwall CS3000 plus (Fenwall, Deerfield, IL, USA) or Cobe Spectra cell separator (Cobe, Lakewood, CO, USA). A second mobilization procedure identical to the first was performed in donors in whom the mobilized stem cell number was regarded as too low, or for retransplantation after rejection.
Isolation of CD34
ϩ progenitor cells CD34 ϩ cells were separated using a modified semi-automated MACS-technique (SuperMacs; Miltenyi Biotec, Bergisch-Gladbach, Germany) as described 13 or with the automated CliniMacs device (Miltenyi Biotec).
14 The mean number of purified CD34 ϩ cells obtained from the 39 donors was 20.7 Ϯ 9.9 ϫ 10 
Myeloablative therapy and reconditioning regimen
The myeloablative therapy and reconditioning regimen are outlined in Figure 2 . The myeloablative regimen consisted in 18 patients of busulfan (age Ͼ3 years, 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg)); age Ͻ3 years, 5 mg/kg p.o. in divided doses daily for 4 days (total 20 mg/kg); thiotepa (10 mg/kg i.v. in two divided doses for 1 day); cyclophosphamide (50 mg/kg i.v. once daily for 4 days (total dose 200 mg/kg) and horse antithymocyte globulin (ATG; 20 mg/kg i.v. daily for 3 days (total 60 mg/kg)) or rabbit anti-lymphocyte globulin (ALG; 10 mg/kg i.v. daily for 3 days (total 30 mg/kg)) (Figure 2a ) or in five patients of fractionated total body irradiation (12 Gy), thiotepa (10 mg/kg), cyclophosphamide (60 mg/kg i.v. for 2 days (total 120 mg/kg)) and ATG ( Figure 2b ). In two patients with SCID (TϪ, Bϩ, NKϪ), purified CD34 ϩ cells were infused without any preparative regimen. An immunological reconditioning regimen consisting of the anti-CD3 antibody OKT-3 (Orthoclone; Cilag, Germany) in combination with methylprednisolone from day Ϫ2 to day ϩ28 ( Figure 2c ) was used for the second transplant in five patients when there had been nonengraftment or rejection of the first transplant. Due to the high nonengraftment/rejection rate and the encouraging experience with the immunological reconditioning regimen, we treated the last 14 of the 39 patients with a combination of busulfan (11 patients) or TBI (three patients) and a short course of OKT-3 plus methylprednisolone rejection prophylaxis from day ϩ1 to day ϩ18 following myeloablative treatment as outlined in Figure 2d .
Engraftment monitoring, T cell add back and immunological reconstitution
Engraftment of the purified CD34 ϩ progenitors after the myeloablative therapy was monitored as described. 15 In 21 patients, CD3
ϩ T lymphocytes freshly obtained from the donor were added back in varying amounts ranging from 2.5 ϫ 10 4 to 1 ϫ 10 5 /kg and at varying stages after transplantation. This included patients who showed a transient mixed chimerism after transplantation or who were not in remission at the time of transplant and therefore considered to be at high risk of relapse. The post-transplant immunological reconstitution of CD3 ϩ , CD4 ϩ , CD19 ϩ and CD56 ϩ lymphocytes was monitored at 1-or 2-weeks intervals in the earlier recovery phase and later every 3 months.
Statistical analysis
For statistical analysis, the logrank test was used. Survival was calculated according to the Kaplan-Meier method.
Results

Engraftment
A rapid primary engraftment was seen in 36 patients with a median of 11 days to reach Ͼ0.5 ϫ 10 9 /l neutrophils, whereas three patients did not engraft. In two patients with primary engraftment, rejection occurred. After immunological reconditioning (Figure 2c ) and transplantation of purified CD34 ϩ cells from the same donor, all but one patient engrafted permanently. This was a patient with a long history of severe aplastic anemia who did not engraft despite a third transplant using an unrelated donor. After the experience with five nonengraftments/rejections, the monoclonal anti-CD3 antibody OKT-3 was added to the conditioning regimen (Figure 2d ) in the last 14 patients and so far no engraftment failure has been seen. Altogether, the overall engraftment rate was 97%.
Donor T cell add back (DLI) and graft-versus-host disease
In the first seven patients, a short-term (Ͻ4 weeks) GVHD prophylaxis with CsA was performed until it was clear that the positive selection of CD34 ϩ cells by MACS was efficient enough to omit any pharmacological GVHD prophylaxis in the following patients. In the absence of T cell add backs, GVHD was not seen in 32 of the 38 evaluable patients. GVHD grade I and grade II occurred in five and one patients, respectively.
In 21 patients, 2.5 ϫ 10 4 to 1 ϫ 10 5 T cells/kg were added back starting at various time intervals after the infusion of the CD34 ϩ cells. DLI was performed once in nine patients, twice in seven, thrice in four and four times in one patient. After DLI, GVHD grade 1 occurred in two patients, grade 2 in three and grade 4 in one patient. In one patient, a chronic GVHD was induced. These data are summarized in Table 2 .
Immunological reconstitution
The reconstitution of T lymphocytes was dependent on the number of transplanted CD34 ϩ cells. The median time to (Figure 3 ). For the B and NK cell recovery, no significant difference was seen (data not shown). There was no delayed CD3 ϩ T cell reconstitution in the patients receiving the anti-CD3 monoclonal antibody from day ϩ1 to day ϩ18 for rejection prophylaxis (data not shown). A longer follow-up of the immunological reconstitution of all evaluable patients showed a normalization of the lymphocyte subsets after 3-6 months ( Figure  4 ). /kg and Ͻ20 ϫ 10 6 /kg purified CD34 ϩ progenitor cells. A significantly faster reconstitution of CD3 ϩ T lymphocytes (P = 0.0065) was seen in patients who were transplanted with Ͼ20 ϫ 10 6 /kg CD34 ϩ cells. 
Survival
Of the 39 patients, 15 are alive and disease-free with a median follow-up of 2 years (range 1-4.5 years; latest follow-up June 2000). The patient with osteopetrosis showed an autologous reconstitution 2 years after transplantation using a busulfan-based preparative regimen and received a second successful transplant after a TBI-based conditioning regimen from the same haploidentical donor. The causes of death were relapse (13 patients), VOD (two patients), viral infection (five patients), fungal infection (two patients), nonengraftment (one patient) and one patient died due to a nontransplant-related cause while in remission. The disease-free survival for patients with malignant and nonmalignant disease is shown in Figure 5a . In Figure 5b , the survival of patients with malignant disease in remission or nonremission at the time of transplantation is shown and Figure 5c depicts the survival for patients with ALL in remission or nonremission at time of transplantation.
Discussion
The transplantation of T cell-depleted, partially matched bone marrow cells has been reported in a considerable number of patients without a suitable donor and for whom stem cell transplantation was the only curative therapeutic option. However, these transplantations were associated with a high incidence of graft failure, GVHD, and severe infectious complications due to the delayed immunological recovery associated with T cell depletion. 16 As it is now possible to augment the stem cell number by mobilization with G-CSF 17 and now that it has been found in animal models that the transplantation of megadoses of purified hematopoietic stem cells can overcome HLA barriers, this transplantation procedure has become a therapeutic option. By using mobilized PBSC, the number of CD34 ϩ progenitors can be drastically increased compared to that obtainable from bone marrow. The complete removal of T lymphocytes from the graft either by a combination of negative and positive selection as described by Aversa et al 12 or by a one-step positive selection of CD34 ϩ cells as described by us 13, 14 must be performed in order to avoid post-transplant immunosuppression for GVHD prophylaxis and GVHD itself. However, T lymphocyte depletion was associated with delayed immunological recovery in the adult patients, resulting in a high incidence of fatal infections. 12 Therefore, we asked whether increasing the number of T cell-depleted purified CD34 ϩ cells and thus increasing the number of transplanted putative lymphoid progenitors would result in a faster immunological recovery.
Indeed, we found that the absence of any immunosuppression and the transplantation of high numbers of purified CD34 ϩ progenitors resulted in rapid immunological recovery. When the number of transplanted CD34 ϩ cells was Ͼ20 ϫ 10 6 /kg, the time to reach subnormal or normal CD3 T lymphocyte levels was relatively short. Fatal infections (five viral, two fungal) were seen in seven patients (18%). These findings in pediatric patients compare favorably to those by Aversa et al, 12 who reported successful haploidentical transplantations in adult patients with T cell depleted PBSC, but noted a higher incidence of early lethal infections due to a delayed immunological reconstitution. This difference between children and adults might be explained by an increased thymic involution in adults associated with a slower reconstitution of the T cell system. However, the average number of transplanted CD34 ϩ cells in Aversa's study was much lower than in our study. From our findings we conclude that the target cell dose of transplanted CD34 ϩ cells should be in the range of 20 ϫ 10 6 /kg in order to achieve rapid immunological reconstitution.
A rapid T cell recovery might also prevent the development of donor-derived B cell lymphoproliferative diseases, which have been seen at high rates early after transplantation of T cell-depleted bone marrow. 18, 19 The combination of rapid T cell recovery and the transplantation of highly purified positively selected CD34 ϩ cells, resulting in both T and B cell depletion, might have been responsible for the fact that none of our patients developed an EBV-associated lymphoproliferative syndrome.
Primary nonengraftment was seen in three patients, in all of whom the number of transplanted CD34 ϩ cells was Ͻ10 ϫ 10 6 /kg. However, in two of these patients, engraftment was achieved after immunological reconditioning and a second transplant with a higher stem cell dose obtained from the same donor. This suggests that the stem cell dose should exceed 10 ϫ 10 6 /kg in order to achieve safe engraftment. One multitransfused patient with long-standing severe aplastic anemia (Ͼ5 years) did not engraft although he had received a higher stem cell dose. This failure may have also been due to the sensitization to HLA antigens induced by the long transfusion history in this patient. In two patients, rejection occurred despite the transplantation of large numbers of CD34 ϩ cells. These rejections were mediated by alloreactive residual host T lymphocytes that had not been completely eliminated by the myeloablative therapy. However, both patients were successfully retransplanted using the same stem cell donors, and rapid and sustained three-lineage engraftment was seen after suppression of these residual T lymphocytes using the immunological reconditioning regimen consisting of anti-CD3 antibodies and steroids (Figure 2c ). After this experience, we decided to combine the myeloablative therapy with immunological conditioning by the administration of the anti-CD3 antibody OKT-3 and steroids starting from day ϩ1 until day ϩ18 (Figure 2d ). This preparative regimen is well tolerated, does not impair T cell reconstitution and no rejection has yet occurred in the 14 patients treated with this regimen. However, it is not yet clear what mechanisms, besides the conditioning regimen, facilitate the engraftment of megadoses of CD34 ϩ cells across the HLA barrier. One possibility is that megadoses of CD34 ϩ stem cells induce tolerance across the HLA barrier. 20 Further clinical application of the megadose concept should show whether the HLA barrier can be overcome with fewer cytotoxic regimens and higher stem cell numbers.
The transplant-related side-effects were acceptable and the main cause of death in our patient group was relapse of the malignant disease. This may have been due to the T cell depletion, since T cell depletion and absence of GVHD in matched transplants is associated with a higher risk of relapse. 21 Therefore, we used T cell add backs for patients who were considered at high risk of relapse or who showed transient autologous hematopoietic recovery. However, no clear conclusions can be drawn at this stage as to whether the add back of T cells in our setting has an antileukemic effect. In our experience, however, there is no safe threshold below which T cells can be safely added back without the risk of GVHD grade II or higher. The add back of other potential antileukemic lymphocyte subpopulations such as natural killer (NK) cells, as described in an animal model 22, 23 is currently under active investigation at our institution. 24 Another reason for relapse may have been the status of disease at the time of transplantation. Fourteen of our patients were completely resistant to chemotherapy and were not in remission prior to transplantation. These patients are at extremely high risk of relapse, even after standard sibling bone marrow transplantation. Therefore, additional conditioning regimens such as radiolabeled antibodies, monoclonal antibodies 25 and post-transplant immunotherapeutic strategies such as therapy with interleukin-2 26 monoclonal antibodies 27 or combinations thereof 28 have to be evaluated for these patients in particular.
In summary, we have shown that the transplantation of megadoses of mismatched parental purified stem cells resulted in complete and sustained engraftment, even after a non-radiotherapy-based conditioning regimen. The incidence of transplant-related side-effects or severe infections was acceptable and, because of the permanent availability of the donor, a second transplant has been possible in case of nonengraftment or rejection. However, by combining the chemo/radiotherapy-based myeloablative regimen with short-term immunosuppression using an anti-CD3 antibody, rejection or nonengraftment could be avoided without compromising the immunological reconstitution. Because of the continued availability of the donor, post-transplant immunotherapeutic strategies using defined antileukemic donor lymphocyte subpopulations can now be evaluated systematically.
Our method offers a realistic therapeutic option for almost every child for whom no suitable donor can be identified within a certain time limit.
